Alnylam Pharmaceuticalsvs.Gilead Sciences
ALNY vs GILD · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Gilead Sciences is about 6.0× larger than Alnylam Pharmaceuticals by market cap; year to date, Gilead Sciences leads (+19.6% vs −43.6%).
Side by side
| ALNY | GILD | |
|---|---|---|
| Market cap | $30B | $180B |
| Price | $224.53 | $147.10 |
| Today | +0.1% | +0.2% |
| Return YTD | −43.6% | +19.6% |
| Return 1Y | −51.2% | +25.7% |
| Since June 26, 2026 | −22.9% | +15.0% |
| P/E | 37.2 | — |
| P/S | 6.3 | 5.9 |
| P/B | 22.2 | 15.2 |
Data as of 2026-10-08 · updates daily after U.S. close
Since June 26, 2026: the change in the closing price, from the daily closes Sectivia records itself since that date.
The two companies
Alnylam PharmaceuticalsALNY
Turns RNA interference into drugs, mostly for rare and cardiovascular disease.
Full ALNY profile →Gilead SciencesGILD
HIV treatment is the heart of it, Biktarvy above all, with cell therapy in oncology growing alongside.
Full GILD profile →More ALNY & GILD comparisons
Other head-to-heads in the Biotech & innovation segment.
See where ALNY and GILD sit in the full Medicine, pharma & life science map: every segment from suppliers to end markets.Open the Life science value chain →